Nugenerex Immuno-Oncology Liabilities 2024

Nugenerex Immuno-Oncology Aktienanalyse

What does Nugenerex Immuno-Oncology do?

Nugenerex Immuno-Oncology Inc is an emerging company in cancer research and treatment. It was founded in 2003 by Dr. William J. Garner and is headquartered in San Diego, California. The origins of Nugenerex Immuno-Oncology lie in the exploration of RNA interference (RNAi) and the development of therapeutics for the treatment of cancer and other diseases. In 2006, the company made a groundbreaking discovery by developing a novel technology called "Blank Gene Therapy," which has the potential to revolutionize cancer treatment. Nugenerex Immuno-Oncology is an innovative biotechnology company focused on developing cancer treatments based on the patient's own immune system. The company has a division for cancer research and development and a division for medical services, combining scientific expertise with a global presence. In its research and development division, Nugenerex Immuno-Oncology focuses on developing novel immunological therapies based on "Blank Gene Therapy." These therapies aim to stimulate the patient's immune system to recognize and destroy cancerous cells. In addition to research and development, the company also offers medical services. The medical services division provides patients and healthcare providers worldwide with access to the latest cancer treatments and clinical trials. By collaborating with doctors and hospitals worldwide, patients gain access to innovative cancer treatments tailored to their specific case. The company has several products in development, including a novel immunotherapeutic called "Enrichin." It is based on "Blank Gene Therapy" and aims to stimulate the patient's immune system to recognize and destroy tumor-like cells. Additionally, the company is working on the development of antibody therapeutics and oncolytic viruses to destroy cancer cells. Nugenerex Immuno-Oncology has also formed a partnership with a leading pharmaceutical company to develop therapeutics for multiple sclerosis and other autoimmune diseases. In summary, Nugenerex Immuno-Oncology is an emerging company in cancer research and treatment, focusing on novel immunological therapies. With its products, services, and global presence, it aims to improve the lives of cancer patients worldwide. Nugenerex Immuno-Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Nugenerex Immuno-Oncology's Liabilities

Nugenerex Immuno-Oncology's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Nugenerex Immuno-Oncology's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Nugenerex Immuno-Oncology's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Nugenerex Immuno-Oncology's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Nugenerex Immuno-Oncology’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Nugenerex Immuno-Oncology stock

What is the level of liabilities of Nugenerex Immuno-Oncology this year?

Nugenerex Immuno-Oncology has a debt balance of 0 USD this year.

What were the liabilities of Nugenerex Immuno-Oncology compared to the previous year?

The liabilities of Nugenerex Immuno-Oncology have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Nugenerex Immuno-Oncology?

High liabilities can pose a risk for investors of Nugenerex Immuno-Oncology, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Nugenerex Immuno-Oncology?

Low liabilities mean that Nugenerex Immuno-Oncology has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Nugenerex Immuno-Oncology affect the company?

An increase in liabilities of Nugenerex Immuno-Oncology can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Nugenerex Immuno-Oncology affect the company?

A decrease in the liabilities of Nugenerex Immuno-Oncology can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Nugenerex Immuno-Oncology?

Some factors that can influence the liabilities of Nugenerex Immuno-Oncology include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Nugenerex Immuno-Oncology so important for investors?

The liabilities of Nugenerex Immuno-Oncology are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Nugenerex Immuno-Oncology take to modify the liabilities?

To change its liabilities, Nugenerex Immuno-Oncology can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Nugenerex Immuno-Oncology pay?

Over the past 12 months, Nugenerex Immuno-Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nugenerex Immuno-Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Nugenerex Immuno-Oncology?

The current dividend yield of Nugenerex Immuno-Oncology is .

When does Nugenerex Immuno-Oncology pay dividends?

Nugenerex Immuno-Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nugenerex Immuno-Oncology?

Nugenerex Immuno-Oncology paid dividends every year for the past 0 years.

What is the dividend of Nugenerex Immuno-Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nugenerex Immuno-Oncology located?

Nugenerex Immuno-Oncology is assigned to the '-' sector.

Wann musste ich die Aktien von Nugenerex Immuno-Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nugenerex Immuno-Oncology from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Nugenerex Immuno-Oncology pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Nugenerex Immuno-Oncology in the year 2023?

In the year 2023, Nugenerex Immuno-Oncology distributed 0 USD as dividends.

In which currency does Nugenerex Immuno-Oncology pay out the dividend?

The dividends of Nugenerex Immuno-Oncology are distributed in USD.